June 2012 - Optimer Pharmaceuticals, Inc. Partnership

ST partners with US-based biopharmaceutical company Optimer Pharmaceutics, Inc. acquiring exclusive rights to market DIFICID^® (fidaxomicin) in Australia and New Zealand